[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613584":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":56,"centralContacts":57,"locations":63,"responsibleParty":79,"collaborators":56,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":56,"eligibilityCriteria":86,"healthyVolunteers":83,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":56,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":65,"whyStopped":56,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"General Hospital of Ningxia Medical University","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Group C(Control Group)","ACTIVE_COMPARATOR","At the beginning of the operation, intravenous infusion of reifentanil 0.1\\~0.2μg\u002Fkg\u002Fmin, propofol 2\\~4mg\u002Fkg\u002Fh, rocuronium 0.3mg\u002Fkg\u002Fh intermittently, inhalation of 1%\\~2% sevoflurane were maintained, the fluctuation of blood pressure was not more than 20% of the basic level, and the heart rate was 50\\~100 times \u002Fmin. 10 minutes before the infusion proper amount of normal saline was administered to the patient. Subsequnetly, a continuous intravenous infusion proper amount of normal saline was maintained until the end of the sugery. Before closing the abdominal cavity, 20ml normal saline was administered.",[13],"Drug: Saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Group IV(Intravenous injection of lidocaine Group)","EXPERIMENTAL","At the beginning of the operation, intravenous infusion of reifentanil 0.1\\~0.2μg\u002Fkg\u002Fmin, propofol 2\\~4mg\u002Fkg\u002Fh, rocuronium 0.3mg\u002Fkg\u002Fh intermittently, inhalation of 1%\\~2% sevoflurane were maintained, the fluctuation of blood pressure was not more than 20% of the basic level, and the heart rate was 50\\~100 times \u002Fmin. 10 minutes before the infusion 2% lidocaine (1.5mg\u002Fkg) was administered to the patient. Subsequnetly, a continuous intravenous 2% lidocaine (2mg\u002Fkg\u002Fh) was maintained until the end of the sugery. Before closing the abdominal cavity, 20ml normal saline was administered.",[19],"Drug: intravenous +saline lidocaine",{"label":21,"type":16,"description":22,"interventionNames":23},"Group IP(Intraperitoneal spray of lidocaine Group)","At the beginning of the operation, intravenous infusion of reifentanil 0.1\\~0.2μg\u002Fkg\u002Fmin, propofol 2\\~4mg\u002Fkg\u002Fh, rocuronium 0.3mg\u002Fkg\u002Fh intermittently, inhalation of 1%\\~2% sevoflurane were maintained, the fluctuation of blood pressure was not more than 20% of the basic level, and the heart rate was 50\\~100 times \u002Fmin. 10 minutes before the infusion proper amount of normal saline was administered to the patient. Subsequnetly, a continuous intravenous infusion proper amount of normal saline was maintained until the end of the sugery. Before closing the abdominal cavity, 2% lidocaine (4-5mg\u002Fkg) + 1\u002F200,000 epinephrine was spraged into the abdominal cavity.",[24],"Drug: saline + intraperitoneal lidocaine",{"label":26,"type":16,"description":27,"interventionNames":28},"Group IVPL(Intravenous and Intraperitoneal spray of lidocaine Group)","At the beginning of the operation, intravenous infusion of reifentanil 0.1\\~0.2μg\u002Fkg\u002Fmin, propofol 2\\~4mg\u002Fkg\u002Fh, rocuronium 0.3mg\u002Fkg\u002Fh intermittently, inhalation of 1%\\~2% sevoflurane were maintained, the fluctuation of blood pressure was not more than 20% of the basic level, and the heart rate was 50\\~100 times \u002Fmin. 10 minutes before the infusion 2% lidocaine (1.5mg\u002Fkg) was administered to the patient. Subsequnetly, a continuous intravenous infusion 2% lidocaine ( 2mg\u002Fkg\u002Fh) was maintained until the end of the sugery. Before closing the abdominal cavity, 2% lidocaine (4-5mg\u002Fkg) + 1\u002F200,000 epinephrine was spraged into the abdominal cavity.",[29],"Drug: intravenous + intraperitoneal lidocaine",[31,38,44,50],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","Saline","10 minutes before the infusion saline 1.5mg\u002Fkg was administered to the patient. Subsequnetly, a continuous intravenous infusion saline 2mg\u002Fkg\u002Fh was maintained until the end of the sugery. Before closing the abdominal cavity, 20ml normal saline was administered.",[9],[37],"placebo",{"type":32,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"intravenous +saline lidocaine","10 minutes before the infusion 2% lidocaine 1.5mg\u002Fkg was administered to the patient. Subsequnetly, a continuous intravenous infusion 2% lidocaine 2mg\u002Fkg\u002Fh was maintained until the end of the sugery. Before closing the abdominal cavity, 20ml normal saline was administered.",[15],[43],"analgesic",{"type":32,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"saline + intraperitoneal lidocaine","10 minutes before the infusion saline 1.5mg\u002Fkg was administered to the patient. Subsequnetly, a continuous intravenous infusion saline ( 2mg\u002Fkg\u002Fh) was maintained until the end of the sugery. Before closing the abdominal cavity, 2% lidocaine (4-5mg\u002Fkg) + 1\u002F200,000 epinephrine was spraged into the abdominal cavity.",[21],[49],"intraperitoneal spary of lidocaine",{"type":32,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"intravenous + intraperitoneal lidocaine","10 minutes before the infusion 2% lidocaine (1.5mg\u002Fkg) was administered to the patient. Subsequnetly, a continuous intravenous infusion 2% lidocaine ( 2mg\u002Fkg\u002Fh) was maintained until the end of the sugery. Before closing the abdominal cavity, 2% lidocaine (4-5mg\u002Fkg) + 1\u002F200,000 epinephrine was spraged into the abdominal cavity.",[26],[55],"intravenous and intraperitoneal injection of lidocaine",null,[58],{"name":59,"role":60,"phone":61,"phoneExt":56,"email":62},"Ma Hanxaing","CONTACT","86-13519591508","mahanxiang@hotmail.com",[64],{"facility":5,"status":65,"city":66,"state":67,"zip":56,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"RECRUITING","Yinchuan","Ningxia","China","CN",{"type":71,"coordinates":72},"Point",[73,74],106.27306,38.46806,{"lat":74,"lon":73},[77],{"name":78,"role":60,"phone":61,"phoneExt":56,"email":62},"Ma Han xiang",{"type":80,"investigatorFullName":56,"investigatorTitle":56,"investigatorAffiliation":56,"oldNameTitle":56,"oldOrganization":56},"SPONSOR","100613584","the-impact-of-intraperitoneal-spray-combined-with-intravenous-lidocaine-on-postoperative-pain-after-myomectomy-100613584",false,"NCT07268495","The Impact of Intraperitoneal Spray Combined With Intravenous Lidocaine on Postoperative Pain After Myomectomy","Inclusion Criteria:\n\n1. Age:18-65 years old;\n2. ASA physical status classification I - III;\n3. Undergoing laparoscopic hysteromyoma resection under general anesthesia;\n4. The patient has been informed and has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Surgery duration exceeding 3 hours;\n2. Need for additional surgery;\n3. Allergy to the study drugs;\n4. Presence of severe psychological,hepatic,renal,and cardiac diseases;\n5. History of chronic pain or arrhythmia.\n\nElimination Criteria:\n\n1. The patient or their family withdraws from or refuses to participate in the trial during the observation period;\n2. Conversion from laparoscopy to laparotomy or change in surgical approach during the procedure.","FEMALE","18 Years","65 Years",{"count":91,"type":92},100,"ESTIMATED","INTERVENTIONAL",[95],"NA","The purpose of this study is to determine whether laparoscopic spraying combined with intravenous injection of lidocaine can improve pain in patients undergoing laparoscopic myomectomy under general anesthesia.",[98],"Postoperative Pain",[100,101,102,103],"lidocaine","myomectomy","laparoscopic surgery","postoperative pain","2025-11-25",{"date":106,"type":107},"2025-12-05","ACTUAL",{"date":109,"type":107},"2024-08-01",{"date":111,"type":92},"2025-12-20",{"name":5,"class":6},1]